Examining Discontinuation Outcomes of EV in Metastatic Urothelial CarcinomaByJoy Li, MDMarch 13th 2026Among patients who discontinued enfortumab vedotin due to an ongoing response or toxicity, 57% were treatment-free and alive 1 year later.